The Fibroblast platform serves as the foundation for developing biologic cures and treatments for chronic diseases, including degenerative disc disease, multiple sclerosis, wound healing ...

MSD (Merck & Co) has signed a license and collaboration agreement with Mestag Therapeutics to develop new fibroblast therapies for inflammatory diseases – a deal potentially worth $1.9bn The ...